Asia-Pacific Acute Myeloid Leukemia Treatment Market - Growth, Trends, COVID-19 Impact, and Forecasts (2021 - 2026)

The Asia-Pacific Acute Myeloid Leukemia Treatment Market is Segmented by Therapy (Chemotherapy, Targeted Therapy, Stem Cell Transplant, Other Therapies), and Geography

Market Snapshot

CAGR
Study Period: 2018 - 2026
Base Year: 2020
CAGR: 8.15 %

Need a report that reflects how COVID-19 has impacted this market and its growth?

Market Overview

There has been an increasing trend in the AML cases seen in the Asian region that has increased the number of clinical trials into new therapies for leukemia patients. In Japan, approximately 4,500 patients are being diagnosed with AML every year, according to a 2018 report by Astellas Pharma Inc. Moreover, the survey has also reported that the prevalence of AML is higher in the geriatric population. As the geriatric population is increasing in percentage, this disease may cause an economic burden on the overall population.

According to a report by Elton B. Stephens Co.(EBSCO) 2017, the prevalence (5-year period) of AML in lower-income Asia-Pacific countries and high-income Asia- Pacific countries was 4 per 100,000 and 7 per 100,000, respectively. Asia-pacific comprises of countries that are not only economically developing, but their population is also increasing every year at a significant rate. Hence as the population of these countries increases, the risk of incidence of AML is also high.

Thus owing to the increase in the prevalence of AML in the Asia-Pacific region, this market is expected to grow during the forecast period.

Scope of the Report

As per the scope of the report, acute myeloid leukemia is also known as acute myelogenous leukemia, acute myeloblastic leukemia, acute granulocytic leukemia, or acute non-lymphocytic leukemia. In acute myeloid leukemia, there is a rapid production of abnormal white blood cells, which get collected in the bone marrow and disturb the production of normal blood cells.

By Therapy
Chemotherapy
Anthracycline Drugs
Alkylating Agents
Anti-metabolites
Other Chemotherapies
Targeted Therapy
Stem Cell Transplant
Other Therapies
Geography
Asia Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific

Report scope can be customized per your requirements. Click here.

Key Market Trends

Chemotherapy is thus Expected to Hold the Largest Market Share During the Forecast Period

Chemotherapy is the main treatment for most people with acute myeloid leukemia (AML). Induction is the first phase of treatment. It is short and intensive, typically lasting about a week. The goal is to clear the blood of leukemia cells (blasts) and to reduce the number of blasts in the bone marrow to normal. Consolidation is chemo given after the patient has recovered from induction. It is meant to kill the small number of leukemia cells that are still around but can’t be seen (because there are so few of them). For consolidation, chemo is given in cycles, with each period of treatment followed by a rest period to allow the body time to recover. A third phase called maintenance (or post-consolidation) involves giving a low dose of chemo for months or years after the consolidation is finished. This is often used to treat acute promyelocytic leukemia (APL), but it is rarely used for other types of AML.

Drugs like Daunomycin, Idarubicin, and Mitoxantrone have been dominated the market, and new research discoveries are expected to further help the growth of this segment. Moreover, the prevalence of leukaemia is increasing and AML is one of the most common causes of death in leukaemia. Hence the incidence of AML is also expected to increcase in Asia. This will increase the demand of AML treatment, helping the market growth.

graphAMLAsia-2.png

Competitive Landscape

The market for acute myeloid leukemia treatment in Asia-Pacific is moderately competitive and comprises of the global players majorly. Some of the key players in this market are Novartis AG, Pfizer Inc., Teva Pharmaceuticals, AbbVie Inc., among others. With the rising focus of pharmaceutical companies to provide better therapeutics for cancer, it is believed that more companies will be penetrating the market in the near future.

Table of Contents

  1. 1. INTRODUCTION

    1. 1.1 Study Deliverables

    2. 1.2 Study Assumptions

    3. 1.3 Scope of the Study

  2. 2. RESEARCH METHODOLOGY

  3. 3. EXECUTIVE SUMMARY

  4. 4. MARKET DYNAMICS

    1. 4.1 Market Overview

    2. 4.2 Market Drivers

      1. 4.2.1 High Incidence and Prevalence of Acute Myeloid Leukemia

      2. 4.2.2 Advancement in Pharmacology and Molecular Biology to Promote Drug Development

    3. 4.3 Market Restraints

      1. 4.3.1 Complications Related to Chemotherapy

    4. 4.4 Porter's Five Force Analysis

      1. 4.4.1 Threat of New Entrants

      2. 4.4.2 Bargaining Power of Buyers/Consumers

      3. 4.4.3 Bargaining Power of Suppliers

      4. 4.4.4 Threat of Substitute Products

      5. 4.4.5 Intensity of Competitive Rivalry

  5. 5. MARKET SEGMENTATION

    1. 5.1 By Therapy

      1. 5.1.1 Chemotherapy

        1. 5.1.1.1 Anthracycline Drugs

        2. 5.1.1.2 Alkylating Agents

        3. 5.1.1.3 Anti-metabolites

        4. 5.1.1.4 Other Chemotherapies

      2. 5.1.2 Targeted Therapy

      3. 5.1.3 Stem Cell Transplant

      4. 5.1.4 Other Therapies

    2. 5.2 Geography

      1. 5.2.1 Asia Pacific

        1. 5.2.1.1 China

        2. 5.2.1.2 Japan

        3. 5.2.1.3 India

        4. 5.2.1.4 Australia

        5. 5.2.1.5 South Korea

        6. 5.2.1.6 Rest of Asia-Pacific

  6. 6. COMPETITIVE LANDSCAPE

    1. 6.1 Company Profiles

      1. 6.1.1 Astellas Pharma Inc.

      2. 6.1.2 AbbVie Inc.

      3. 6.1.3 Celgene Corporation

      4. 6.1.4 Daiichi Sankyo Company Limited

      5. 6.1.5 Novartis AG

      6. 6.1.6 Pfizer Inc.

      7. 6.1.7 Teva Pharmaceutical Industries Ltd

      8. 6.1.8 Mylan NV

      9. 6.1.9 Sun Pharmaceutical Industries Ltd

      10. 6.1.10 Fresenius SE & Co. KGaA

    2. *List Not Exhaustive
  7. 7. MARKET OPPORTUNITIES AND FUTURE TRENDS

**Subject to Availability
**Competitive Landscape covers- Business Overview, Financials, Products and Strategies and Recent Developments

You can also purchase parts of this report. Do you want to check out a section wise price list?

Frequently Asked Questions

The Asia-Pacific Acute Myeloid Leukemia Treatment Market | Growth, Trends, and Forecast (2020 - 2025) market is studied from 2018 - 2026.

The Asia-Pacific Acute Myeloid Leukemia Treatment Market | Growth, Trends, and Forecast (2020 - 2025) is growing at a CAGR of 8.15% over the next 5 years.

AbbVie Inc., Novartis AG, Pfizer Inc., Teva Pharmaceutical, Sun Pharmaceutical Industries Ltd are the major companies operating in Asia-Pacific Acute Myeloid Leukemia Treatment Market | Growth, Trends, and Forecast (2020 - 2025).

80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Please enter a valid email id!

Please enter a valid message!